Moderna, Inc.
419 articles with Moderna, Inc.
-
Moderna Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)
10/22/2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has completed enrollment of 30,000 participants for the Phase 3 COVE study of mRNA-1273, its vaccine candidate against COVID-19, being conducted in collaboration with National Institute of Allergy and Infectious Diseases (NIAID)
-
Moderna Fully Enrolls 30,000-Person COVID-19 Vaccine Trial, Boosts Minority Participation
10/22/2020
Moderna has fully enrolled its late-stage coronavirus disease 2019 (COVID-19) vaccine trial by hitting its target of 30,000 participants. More than one-third of this cohort includes minority participants. -
Stephane Bancel, chief executive officer of Moderna, told analysts and journalists at a Wall Street Journal’s Tech Live event on Monday that the FDA requires enough safety and efficacy data, and he believes that they will have that in the later part of November.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
-
Moderna is working with international regulators to accelerate approval of the company’s COVID-19 vaccine candidate, mRNA-1273.
-
Moderna to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020
10/15/2020
Moderna, Inc. announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, October 29, 2020 to report its third quarter 2020 financial results and provide a corporate update.
-
Moderna Receives Confirmation of Eligibility for Submission of Marketing Authorization Application to the European Medicines Agency for mRNA Vaccine Against COVID-19 (mRNA-1273)
10/14/2020
Moderna, Inc. , (Nasdaq:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has received written confirmation from the European Medicine Agency (EMA) that mRNA-1273, the Company’s vaccine candidate ag
-
Moderna Announces Initiation of Rolling Submission to Health Canada for mRNA Vaccine Against COVID-19 (mRNA-1273)
10/13/2020
Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s vaccine candidate against COVID-19. This initi
-
DARPA Awards Moderna up to $56 Million to Enable Small-Scale, Rapid Mobile Manufacturing of Nucleic Acid Vaccines and Therapeutics
10/8/2020
Award part of DARPA’s Nucleic Acids On-Demand World-Wide (NOW) initiative to develop a medical countermeasure manufacturing platform
-
Moderna Announces Updates on Respiratory Syncytial Virus (RSV) Vaccine Program
10/8/2020
Moderna, Inc. announced that it has regained all rights to the respiratory syncytial virus vaccine from Merck, known as MSD outside the United States and Canada, including rights to develop RSV vaccines for adult populations.
-
A few days ago, CNBC reported that five patients, three in Moderna’s and two in Pfizer’s Phase III trials, had experienced more severe, although transient side effects.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 6, 2020.
-
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
-
Moderna published second interim analysis of its open-label Phase I trial of its COVID-19 vaccine, mRNA-1273, in The New England Journal of Medicine.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 30, 2020.
-
Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Older Adult Age Cohorts in Phase 1 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)
9/29/2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of the second interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, in The New England Journal of Medicine.
-
Moderna to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference
9/28/2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Dr. Stephen Hoge, President, will participate in the Chardan Virtual 4th Annual Genetic Medicines Conference on October 5, 2020 at 2:00 p.m. ET.
-
Canada Exercises Increased Option for 20 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
9/22/2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the Canadian Government has increased its confirmed order commitment to 20 million doses of Moderna’s vaccine candidate against COVID-19, mRNA-1273.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.